MANGOCEUTICALS, INC. (MGRX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, MANGOCEUTICALS, INC.'s filing signal continuing negative.

Mangoceuticals, Inc. connects consumers to licensed healthcare professionals via its website for telehealth services, focusing on men's wellness products for erectile dysfunction, hair loss, testosterone replacement, and weight management. The company markets branded compounded products like 'Mango' (ED), 'Grow' (hair loss), 'Mojo' (hormone balance), and 'Slim' (weight loss), alongside an FDA-approved oral testosterone replacement therapy product called 'Prime' powered by Kyzatrex(R). These products are compounded and fulfilled by Epiq Scripts, LLC, a related-party pharmacy. Mangoceuticals also holds patents for respiratory illness prevention technology and plans to license plant-based skin formulations. The company operates primarily in the United States, with its platform serving as the central hub for customer interaction, medical consultations, and pharmacy fulfillment.

Revenue is primarily driven by the sale of its men's wellness products, including compounded formulations and the 'Prime' TRT product, sold directly to consumers through its telemedicine platform.